2022 HKEX Biotech Listings Drop from Last Year’s Record High
After a record year of new biotech listings in 2021, the Hong Kong Stock Exchange (HKEX) has seen a significant drop-off in the first eight months of 2022. The exchange…
MediConcepts was founded with the aim to provide the optimized solutions for medical device design development and manufacturing to a wide range of customers whether they are innovators who need a compliant product development process and collaboration; or projects seeking for a reliable high quality mass production with complete traceability.
Early projects that MediConcepts encountered include redeveloping a two hand operated intra-ocular lens disposable case to an one hand operated casing in late 90’s; and a minimal invasive tissue retrieval system originated from a UK surgeon who is also a pioneer in minimal access surgery in early 2000’s. The design briefs were simply a hand-sketched drawing faxed to us and we delivered a complete design and production in less than 6 months. Since then, our philosophy has been focusing on “design by surgeon for surgeons” medical devices.
The range of products that we now cover are very broad. “Think Medical” is our believe and “Redefine the medical device Contract Manufacturing Experience” is what we want to offer to our customers. Eventually, we want to position MC to be the ideal CM.
Contact
Address 7A-D Hong Kong Industrial Building, 444-452 Des Voeux Road West, Hong Kong
Tel: +852 2838 0300
Website: http://www.mediconcepts.com/
Email: marketing@mediconcepts.com
After a record year of new biotech listings in 2021, the Hong Kong Stock Exchange (HKEX) has seen a significant drop-off in the first eight months of 2022. The exchange…
Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and…
Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong…
Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning…
Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative…
Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy…
Kelvin Chiu and Isabelle Dutry of Sanwa BioTech in Hong Kong highlight the critical importance of personalised fast-track diagnostics in countering the COVID-19 pandemic, the role that Asian firms have…
See our Cookie Privacy Policy Here
